|Mr. Thomas K. Equels Esq., M.S., J.D.||Exec. Vice Chairman, Chief Exec. Officer and Pres||778.27k||N/A||64|
|Mr. Adam Pascale CPA||Chief Financial Officer and Chief Accounting Officer||222.8k||N/A||69|
|Dr. David R. Strayer M.D.||Chief Scientific & Medical Officer||316.81k||N/A||71|
|Mr. Wayne S. Springate||Sr. VP of Operations||N/A||N/A||46|
|Ann Marie E. Coverly||Director of Admin. & HR and Investor Relations Mang.||N/A||N/A||N/A|
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The companys approved products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of sexually transmitted disease infection; and Ampligen, a product approved for sale in Argentina for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma; Alferon N Injection for the treatment of various categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of pandemic influenza, seasonal influenza, and other viruses. The company was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.
Hemispherx Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.